Boyle joins Bionovo

Friday, January 6, 2012 09:21 AM

Bionovo, a pharmaceutical company focusing on women’s health and cancer, has named David Boyle senior vice president and chief financial officer.

Boyle comes to Bionovo with extensive operational and international financial experience, which includes similar titles at AVI BioPharma and XOMA.

"Beyond his extensive background in finance, David brings to Bionovo expertise in several business and operational areas," said Isaac Cohen, Bionovo's chairman and chief executive officer.  "We are excited to have David join our management team here at Bionovo as we move forward the phase III clinical development of Menerba, our drug candidate for the treatment of menopausal hot flashes.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs